Trials / Recruiting
RecruitingNCT06964113
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 19 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Filgotinib Maleate | Administered as oral tablets. |
Timeline
- Start date
- 2025-06-11
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
- First posted
- 2025-05-09
- Last updated
- 2026-01-30
Locations
18 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06964113. Inclusion in this directory is not an endorsement.